NOTE

🌱 created from: acute promyelocytic leukemia (APL)

apollo

APOLLO trial (NCT02688140): ATRA/ATO + idarubicin vs. ATRA/chemotherapy, Event-free survival (EFS) at 2 years: 88% vs. 70% (P = .02), and at 5 years: 87% vs. 55% (P = .0034); hematologic toxicity was significantly lower in the ATRA/ATO arm.

• ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL
• EHA Library - The official digital education library of European Hematology Association (EHA)